Nuance Investments LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 16.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 662,894 shares of the healthcare product maker’s stock after selling 132,441 shares during the quarter. Abbott Laboratories comprises about 2.5% of Nuance Investments LLC’s portfolio, making the stock its 16th biggest holding. Nuance Investments LLC’s holdings in Abbott Laboratories were worth $35,372,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Gratus Capital LLC raised its position in shares of Abbott Laboratories by 0.9% during the 2nd quarter. Gratus Capital LLC now owns 205,067 shares of the healthcare product maker’s stock valued at $9,968,000 after buying an additional 1,869 shares during the period. Vantage Investment Advisors LLC raised its position in shares of Abbott Laboratories by 103.4% during the 2nd quarter. Vantage Investment Advisors LLC now owns 72,161 shares of the healthcare product maker’s stock valued at $3,508,000 after buying an additional 36,683 shares during the period. RKL Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at approximately $227,000. Zurich Insurance Group Ltd FI raised its position in shares of Abbott Laboratories by 2.5% during the 2nd quarter. Zurich Insurance Group Ltd FI now owns 240,866 shares of the healthcare product maker’s stock valued at $11,708,000 after buying an additional 5,790 shares during the period. Finally, Amalgamated Bank raised its position in shares of Abbott Laboratories by 57.6% during the 2nd quarter. Amalgamated Bank now owns 191,206 shares of the healthcare product maker’s stock valued at $9,295,000 after buying an additional 69,871 shares during the period. Institutional investors own 71.21% of the company’s stock.

Several analysts have recently commented on ABT shares. ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays reaffirmed a “buy” rating and set a $66.00 price target on shares of Abbott Laboratories in a research report on Monday, January 8th. BTIG Research lowered shares of Abbott Laboratories from a “buy” rating to a “neutral” rating in a research report on Monday. They noted that the move was a valuation call. Stifel Nicolaus lifted their price target on shares of Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, October 19th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Eight research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $60.24.

Shares of Abbott Laboratories (NYSE:ABT) opened at $59.57 on Tuesday. Abbott Laboratories has a 1-year low of $39.25 and a 1-year high of $59.68. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The firm has a market cap of $103,690.00, a P/E ratio of 49.23, a P/E/G ratio of 1.89 and a beta of 1.55.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 1.88%. The ex-dividend date of this dividend is Thursday, January 11th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. Abbott Laboratories’s dividend payout ratio (DPR) is 92.56%.

In other Abbott Laboratories news, Chairman Miles D. White sold 276,886 shares of the business’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total value of $15,065,367.26. Following the completion of the transaction, the chairman now owns 3,677,913 shares in the company, valued at $200,115,246.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Daniel Gesua Sive Salvadori sold 28,319 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $54.92, for a total transaction of $1,555,279.48. Following the completion of the transaction, the insider now owns 102,117 shares of the company’s stock, valued at approximately $5,608,265.64. The disclosure for this sale can be found here. Insiders sold a total of 404,569 shares of company stock valued at $22,103,095 in the last quarter. 0.76% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This story was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/01/23/abbott-laboratories-abt-shares-sold-by-nuance-investments-llc.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.